Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

被引：0
|
作者：
Hutchings, M. [1 ]
Morschhauser, F. [2 ]
Iacoboni, G. [3 ]
Carlo-Stella, C. [4 ]
Offner, F. C. [5 ]
Sureda, A. [6 ]
Salles, G. [7 ,8 ]
Martinez-Lopez, J. [9 ]
Crump, M. [10 ]
Lundberg, L. [11 ]
Dixon, M. [12 ]
Kwan, A. [13 ]
Wei, M. C. [13 ]
Broeske, A-M E. [14 ]
Carlile, D. [12 ]
O'Hear, C. [13 ]
Dickinson, M. J. [15 ,16 ]
机构：
[1] Rigshosp Copenhagen, Dept Oncol, Copenhagen, Denmark
[2] Ctr Hosp Reg Univ Lille, Lille, France
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Humanitas Univ, Milan, Italy
[5] Univ Ziekenhuis Gent, Ghent, Belgium
[6] Inst Catala Oncol Hospitalet, Barcelona, Spain
[7] Hosp Civils Lyon, Pierre Benite, France
[8] Univ Claude Bernard, Pierre Benite, France
[9] Hosp Univ 12 Octubre H12O, Madrid, Spain
[10] Princess Margaret Hosp, Toronto, ON, Canada
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Roche Prod Ltd, Welwyn Garden City, Herts, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Roche Pharma Res & Early Dev, Roche Innovat Ctr, Penzberg, Germany
[15] Royal Melbourne Hosp, Melbourne, Vic, Australia
[16] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226
引用
收藏
页码：58 / 59
页数：2
相关论文
共 50 条
  • [21] Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)
    Carlo-Stella, Carmelo
    Khan, Cyrus
    Hutchings, Martin
    Offner, Fritz C.
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Sureda, Anna
    Iacoboni, Gloria
    Haioun, Corinne
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Carlile, David
    Piccione, Emily
    Belousov, Anton
    Humphrey, Kathryn
    Dickinson, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S394 - S394
  • [22] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [23] Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).
    Witzig, Thomas E.
    Vose, Julie M.
    Zinzani, Pier Luigi
    Reeder, Craig B.
    Buckstein, Rena
    Polikoff, Jonathan
    Guo, Pingshan
    Pietronigro, Dennis
    Ervin-Haynes, Annette
    Czuczman, Myron S.
    BLOOD, 2009, 114 (22) : 668 - 669
  • [24] Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, P. M.
    Fu, P.
    Lazarus, H. M.
    Bahlis, N. J.
    Koc, O. N.
    Horvath, N. J.
    Cooper, B. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Phase I dose escalation study of fludarabine, bortezomib, and rituximab for relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, P.
    Fu, P.
    Lazarus, H. M.
    Bahlis, N. J.
    Koc, O. N.
    Horvath, N. J.
    Cooper, B. W.
    ANNALS OF ONCOLOGY, 2008, 19 : 209 - 209
  • [26] CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    de Braud, F.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    de Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S464 - S464
  • [27] CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
    Hollebecque, A.
    de Bono, J. S.
    Salvagni, S.
    Plummer, R.
    Niccoli, P.
    Capdevila, J.
    Curigliano, G.
    Moreno, V.
    De Braud, F.
    Lopez-Brea, M.
    Martin-Romano, P.
    Baudin, E.
    Arias, M.
    De Alvaro, J.
    Parra-Palau, J.
    Sanchez-Perez, T.
    Aronchik, I.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2020, 31 : S6 - S6
  • [28] Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
    Fanale, Michelle A.
    Hamlin, Paul A.
    Park, Steven I.
    Persky, Daniel Oscar
    Higgins, Jack P.
    Burnett, Christine
    Dabovic, Kristina
    Poma, Eric
    Sarapa, Nenad
    Younes, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [30] Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHL): updated results from a Phase I/II study
    von Tresckow, B.
    Budde, L. E.
    Bartlett, N. L.
    Giri, P.
    Schuster, S. J.
    Assouline, S.
    Yoon, S. S.
    Fay, K.
    Matasar, M.
    Gutierrez, N. C.
    Marlton, P.
    Dreyling, M.
    Yoon, D. H.
    Hess, G.
    Radford, J.
    Wiebking, V.
    Yin, S.
    Cybulski, E.
    Turner, D. C.
    Huang, H.
    Zhou, M.
    Penuel, E.
    Wei, M. C.
    Sehn, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 206 - 207
12345